Drugs & Targets Tibsovo receives FDA approval for advanced or metastatic cholangiocarcinoma September 03, 2021Vol.47 No.32
Drugs & Targets Opdivo receives FDA approval for adjuvant treatment of urothelial carcinoma September 03, 2021Vol.47 No.32
Drugs & Targets Jemperli receives FDA accelerated approval for dMMR advanced solid tumors September 03, 2021Vol.47 No.32
Drugs & Targets Welireg receives FDA approval in indication for adults with VHL September 03, 2021Vol.47 No.32
Drugs & Targets Keytruda + Lenvima combination receives FDA approval for frontline advanced RCC September 03, 2021Vol.47 No.32
Drugs & Targets FDA accepts sBLA for Keytruda as single agent for MSI-H/dMMR advanced endometrial carcinoma September 03, 2021Vol.47 No.32
Drugs & Targets FDA grants priority review for NDA of asciminib in CML indication September 03, 2021Vol.47 No.32
Drugs & Targets European Commission approves Minjuvi + lenalidomide for relapsed/refractory DLBCL September 03, 2021Vol.47 No.32
